GUTS: Fractyl Health, Inc. Company Short-Term Debt

Symbol and logo of brand Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. (GUTS) is penetrating the growing endoscopic treatment segment for type 2 diabetes by expanding its clinic network. A snapshot of short-term debt within the price action on the GURU.Markets chart reflects the dynamics of liabilities, where the value of 0.00 serves as the baseline indicator. The high pricing power of Revita supports the company, while its financial stability relies exclusively on external investments prior to product commercialization.

GUTS (Fractyl Health Inc.) Company Short-Term Debts history from 02/21/2024 to 10/30/2026

GUTS (Fractyl Health, Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Fractyl Health|GUTS - Fair Value Consensus
- market capitalization information:
Market Value Fractyl Health, Inc.|GUTS - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Fractyl Health|GUTS - Book Capitalization|Market Cap to Net Assets Ratio fractyl.com|GUTS - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Fractyl Health, Inc.|GUTS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Fractyl Health, Inc.|GUTS - Company Cumulative Debt|Debt to Book Value Fractyl Health, Inc.|GUTS - Amount of Long-Term Liabilities|Company Short-Term Debts Fractyl Health|Quick Ratio fractyl.com
- net income and valuation multiples indicators:
GUTS - Company Net Income
Basic company analysis:Fractyl Health - GUTS
Mass-produced product of Fractyl Health, Inc

Fractyl Health, Inc. (GUTS) focuses on the commercialization of the Revita system for the therapy of diabetes and obesity, which requires significant operational capital. Analyzing the change in short-term liabilities, we see a current value of 0.00, reflecting the volume of loans due for repayment within a year; an increase in this metric may indicate heightened financial risks, which directly impacts the stability of the asset's quotes.

Who Fractyl Health, Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|QNCX - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|MTNB (Matinas BioPharma Holdings, Inc.) - Current Liabilities|SPRB - Company Short-Term Debt|Company Short-Term Loans and Borrowings GLTO (Galecto Inc)|CTCX: Company Short-Term Debts|Lumos Therapeutics (LUMO) - Company Short-Term Debts|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Current Liabilities radiuspharm.com (RDUS)